Recent Reports


2010-03-11: Health Care IT Report
6 leading Analysts; and top management from 1 Sector Firm examine this vital industry in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 38 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Analyst Interview Excerpt
THE STIMULUS PACKAGE AND HEALTHCARE IT – BRET JONES – BREAN MURRAY, CARRET & CO., LLC


Full article published: 08/10/2009


For Subscribers

Get this article online now!

Order just this article
TWST: Healthcare IT has become a hot topic, driven by the stimulus package. Is that what's raised the space on investors' lists?
Mr. Jones: Absolutely. I believe the stimulus package has captured the imagination of investors and has dominated the action in the shares of HCIT vendors. If we look back to the second half of 2008, the market was essentially throwing these names aside, as hospitals and physician practices began to rein in their cap ex budgets in reaction to looming unemployment, rising bad debt and losses in their endowments. Investors were shying away from the HCIT vendors, along with other healthcare names tied to capital spending, until President- elect Obama decided to include healthcare IT within the stimulus package. The goal of including HCIT in the ARRA was to jump-start the adoption of electronic medical records within hospitals and physician practices. President-elect Obama made the pronouncement in a radio address in early December and the stocks took off from there. After a dramatic rise in December, the group paused in January and February, as investors grappled with the how and when stimulus funding would be made available.

TWST: Do we have that defined now?
Mr. Jones: We do. The stimulus package was signed into law last February and so established Medicare and Medicaid incentive payments for hospitals and physician practices that have adopted and are meaningful users of a certified electronic health record (EHR). However, the definition of meaningful use and what qualifies as a certified EHR were left up to HHS to determine through several newly created subcommittees within the Office of the National Coordinator for Healthcare Information Technology (ONCHIT). But how the payments are to be issued was established within the stimulus package.

 

Tickers included in this excerpt: ATHN, CERN, CPSI, ECLP, GEOI, MDRX, QSII

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.